secwatch / observer
8-K filed May 15, 2026, 4:03 PM ET ticker CWD CIK 0001627282
other confidence high sentiment neutral materiality 0.10

CaliberCos holds 2026 annual meeting; directors elected, auditor ratified

CaliberCos Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CaliberCos Inc. shareholders approved Ratification of the appointment of Urish Popeck & Co., LLC as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 at the 2026-05-14 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-14
Exact text from the filing
Proposal 2 : Ratification of the appointment of Urish Popeck & Co., LLC as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 5,864,763 66,964 59,024 —
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CaliberCos Inc. shareholders approved Election of five directors to serve for a term ending as of the Company's annual meeting in 2027 at the 2026-05-14 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-14
Exact text from the filing
Proposal 1 : Election of five directors to serve for a term ending as of the Company’s annual meeting in 2027. Director Nominee For Against Abstain Broker Non-Votes John C. Loeffler, II 4,344,746 - 28,874 1,617,131 Jennifer Schrader 4,351,161 - 22,459 1,617,131 William J. Gerber 4,336,718 - 36,901 1,617,132 Lawrence X. Taylor III 4,343,396 - 30,224 1,617,131 Jerome Alan Reid, Jr. 4,344,219 - 29,401 1,617,131
View on SEC.gov

562 shareholder votes filed in the last 30 days. Browse all shareholder votes →

CaliberCos Inc. filing history →

Source: SEC EDGAR
accession 0001627282-26-000037
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.